184 related articles for article (PubMed ID: 37547602)
1. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.
Merli M; Accorinti M; Romagnuolo M; Marzano A; Di Zenzo G; Moro F; Antiga E; Maglie R; Cozzani E; Parodi A; Gasparini G; Sollena P; De Simone C; Caproni M; Pisano L; Fattore D; Balestri R; Sena P; Vezzoli P; Teoli M; Ardigò M; Vassallo C; Michelerio A; Satta RR; Dika E; Melotti B; Ribero S; Quaglino P
Front Med (Lausanne); 2023; 10():1208418. PubMed ID: 37547602
[TBL] [Abstract][Full Text] [Related]
2. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence.
Maliga Z; Kim DY; Bui AN; Lin JR; Dewan AK; Murphy GF; Nirmal AJ; Lian CG; Sorger PK; LeBoeuf NR
bioRxiv; 2023 Apr; ():. PubMed ID: 37066161
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Checkpoint Inhibition Associated Bullous Pemphigoid: A Propensity Matched Retrospective Cohort Study.
Sarkovics K; Kolodney JA; Kolodney MS
Br J Dermatol; 2024 Apr; ():. PubMed ID: 38644763
[No Abstract] [Full Text] [Related]
4. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
Berner F; Flatz L
Immunol Rev; 2023 Sep; 318(1):37-50. PubMed ID: 37548043
[TBL] [Abstract][Full Text] [Related]
5. Serum sodium levels associate with recovery of kidney function in immune checkpoint inhibitor nephrotoxicity.
Tampe D; Baier E; Hakroush S; Tampe B
Front Med (Lausanne); 2023; 10():1020691. PubMed ID: 37547603
[TBL] [Abstract][Full Text] [Related]
6. Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
Flanagan KC; Earls J; Schillebeeckx I; Hiken J; Wellinghoff RL; LaFranzo NA; Bradley ZS; Babbitt J; Westra WH; Hsu R; Nadauld L; Mcleod H; Firth SD; Sharp B; Fuller J; Vavinskaya V; Sutton L; Deichaite I; Bailey SD; Sandulache VC; Rendo MJ; Macdonald OK; Welaya K; Wade JL; Pippas AW; Slim J; Bank B; Saccaro SJ; Sui X; Akhtar A; Balaraman S; Kossman SE; Sonnier SA; Shenkenberg TD; Alexander WL; Price KA; Bane CL; Ley J; Messina DN; Glasscock JI; Cohen EEW; Adkins DR; Duncavage EJ
J Cancer Res Clin Oncol; 2023 Nov; 149(15):14125-14136. PubMed ID: 37552307
[TBL] [Abstract][Full Text] [Related]
7. Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies.
Li X; Lei Y; Liu J; Lin H; Chen K; Yin F; Wang C; Zhang H
Discov Oncol; 2023 Aug; 14(1):146. PubMed ID: 37553451
[TBL] [Abstract][Full Text] [Related]
8. Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions.
Uehara K; Tanoue K; Yamaguchi K; Ohmura H; Ito M; Matsushita Y; Tsuchihashi K; Tamura S; Shimokawa H; Isobe T; Shibata Y; Ariyama H; Tanaka R; Kusaba H; Yamamoto H; Oda Y; Akashi K; Baba E
Cancer Immunol Immunother; 2023 Nov; 72(11):3543-3558. PubMed ID: 37550428
[TBL] [Abstract][Full Text] [Related]
9. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
Townsend MJ; Liu M; Giobbie-Hurder A; Sack JS; LeBoeuf NR; Hodi FS; McNabb-Baltar J; Grover S
J Natl Compr Canc Netw; 2023 Aug; 21(8):831-840.e3. PubMed ID: 37549912
[TBL] [Abstract][Full Text] [Related]
10. First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Nishio M; Ohe Y; Ikeda S; Yokoyama T; Hayashi H; Fukuhara T; Sato Y; Tanaka H; Hotta K; Sugawara S; Daga H; Okamoto I; Kasahara K; Naito T; Li L; Gupta RG; Bushong J; Mizutani H
Int J Clin Oncol; 2023 Oct; 28(10):1354-1368. PubMed ID: 37548831
[TBL] [Abstract][Full Text] [Related]
11. Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.
Hamakawa Y; Agemi Y; Shiba A; Ikeda T; Higashi Y; Aga M; Miyazaki K; Taniguchi Y; Misumi Y; Nakamura Y; Shimokawa T; Saigusa Y; Kobayashi N; Okamoto H; Kaneko T
Cancer Med; 2023 Sep; 12(17):17788-17797. PubMed ID: 37548381
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center.
Roccuzzo G; Giordano S; Granato T; Cavallo F; Mastorino L; Avallone G; Pasini B; Quaglino P; Ribero S
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568588
[TBL] [Abstract][Full Text] [Related]
13. Immune-related adverse events and outcomes among pan-cancer patients receiving immune checkpoint inhibitors: A monocentric real-world observational study.
Ge X; Jiang W; Li H; Wu Y; Li X; Cui S
Cancer Med; 2023 Sep; 12(18):18491-18502. PubMed ID: 37564011
[TBL] [Abstract][Full Text] [Related]
14. A 71-year-old male with a life-threatening recurrence of hemolytic anemia, thrombocytopenia, and acute kidney injury after pembrolizumab therapy: a case report.
Zhang X; Gao BX; Guo CY; Su T
BMC Geriatr; 2023 Aug; 23(1):478. PubMed ID: 37553570
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysis.
Cai Q; Wu W; Li X; Xu Q; Zhao L; Lv Q
J Cancer Res Clin Oncol; 2023 Nov; 149(15):14113-14123. PubMed ID: 37553420
[TBL] [Abstract][Full Text] [Related]
16. Lymph Node Dissection in Intrahepatic Cholangiocarcinoma: a Critical and Updated Review of the Literature.
Lluís N; Asbun D; Wang JJ; Cao HST; Jimenez RE; Alseidi A; Asbun H
J Gastrointest Surg; 2023 Dec; 27(12):3001-3013. PubMed ID: 37550590
[TBL] [Abstract][Full Text] [Related]
17. Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA; Di Giacomo AM; Chiarion Sileni V; Queirolo P; Spagnolo F; De Galitiis F; Cognetti F; Mandalà M; Guidoboni M; Rinaldi G; Depenni R; Consoli F; Troiani T; Guida M; Marconcini R; Ferrucci PF; Strippoli S; Fava P; Merelli B; Simeone E; Di Guardo L; Giannarelli D; Maio M; Quaglino P; Del Vecchio M
Eur J Cancer; 2023 Sep; 191():113246. PubMed ID: 37549531
[TBL] [Abstract][Full Text] [Related]
18. Correction to: Diagnostic Value of the International Society of Cardio-Oncology Definition for Suspected Immune Checkpoint Inhibitor-Associated Myocarditis.
J Am Heart Assoc; 2023 Aug; 12(16):e027735. PubMed ID: 37548155
[No Abstract] [Full Text] [Related]
19. Common clinicopathological and immunological features of sarcomatoid carcinoma across organs: A histomorphology-based cross-organ study.
Morisue R; Kojima M; Suzuki T; Watanabe R; Sakamoto N; Sakashita S; Harada K; Nakai T; Ishii G; Nakatsura T; Gotohda N; Ishikawa S
Int J Cancer; 2023 Dec; 153(12):1997-2010. PubMed ID: 37548077
[TBL] [Abstract][Full Text] [Related]
20. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid.
de Nicolas-Ruanes B; Ballester-Martinez A; Garcia-Mouronte E; Berna-Rico E; Azcarraga-Llobet C; Fernandez-Guarino M
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
